# US 8,278,321 B2 · Small molecule inhibition of intracellular transport

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,321 B2
- Document ID: US8278321B2
- Status: Granted
- Kind: B2
- Application number: 12/645,094
- Filed: 2009-12-22
- Published: 2010-06-24
- Granted: 2012-10-02
- Earliest claimed: 2008-12-23
- Assignees: Washington University
- Inventors: David B. Haslam
- Web page: https://patentgrep.com/patent/US8278321B2

## CPC

- C07K 14/4702: {Regulators; Modulating activity}
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present disclosure characterizes the activity of Golgicide A (GCA), as a potent, specific and reversible small molecule inhibitor of Golgi BFA resistance factor 1 (GBF1) function. A mutant GBF1 gene that is resistant to GCA is also described. Methods of using GCA and the GCA-resistant GBF1 gene are described including methods for modulating GBF1 activity for research and therapeutic purposes. Also described are compositions incorporating a GCA-resistant GBF1.

## Claims

### Claim 1

A method of inhibiting Golgi BFA resistance factor (GBF1) in a eukaryotic cell, the method comprising contacting the cell with Golgicide A.

### Claim 2 (depends on 1)

The method of claim 1, wherein contacting the cell with Golgicide A comprises contacting the cell with a solution of Golgicide A in an organic solvent.

### Claim 3 (depends on 2)

The method of claim 2, wherein the organic solvent is DMSO.

### Claim 4 (depends on 2)

The method of claim 2, wherein the solution of Golgicide A comprises Golgicide A at a concentration of from about 0.1 μM to about 100 μM.

### Claim 5 (depends on 4)

The method of claim 4, wherein the solution of Golgicide A comprises Golgicide A at a concentration of from about 5 μM to about 20 μM.

### Claim 6 (depends on 1)

The method of claim 1, wherein the eukaryotic cell is a mammalian cell.

### Claim 7 (depends on 1)

The method of claim 1, wherein the eukaryotic cell is a human cell.

### Claim 8 (depends on 1)

The method of claim 1, further comprising exposing the cell to a cytotoxin selected from the group consisting of: shiga toxin, cholera toxin, heat labile toxin, heat stable toxin, abrin, and ricin.

### Claim 9 (depends on 1)

The method of claim 1, further comprising at least partially reversing the effect of Golgicide A on GBF1 by wash-out of Golgicide A with a cell medium lacking Golgicide A.
